247 related articles for article (PubMed ID: 31041803)
1. Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
Riedl J; Ay C
Semin Thromb Hemost; 2019 Jun; 45(4):334-341. PubMed ID: 31041803
[TBL] [Abstract][Full Text] [Related]
2. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Mir Seyed Nazari P; Riedl J; Preusser M; Posch F; Thaler J; Marosi C; Birner P; Ricken G; Hainfellner JA; Pabinger I; Ay C
J Thromb Haemost; 2018 Jun; 16(6):1121-1127. PubMed ID: 29676036
[TBL] [Abstract][Full Text] [Related]
3. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.
Riedl J; Preusser M; Nazari PM; Posch F; Panzer S; Marosi C; Birner P; Thaler J; Brostjan C; Lötsch D; Berger W; Hainfellner JA; Pabinger I; Ay C
Blood; 2017 Mar; 129(13):1831-1839. PubMed ID: 28073783
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
Watanabe J; Natsumeda M; Okada M; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
World Neurosurg; 2019 Aug; 128():e982-e988. PubMed ID: 31100523
[TBL] [Abstract][Full Text] [Related]
5. Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Burdett KB; Unruh D; Drumm M; Steffens A; Lamano J; Judkins J; Schwartz M; Javier R; Amidei C; Lipp ES; Peters KB; Lai A; Eldred BSC; Heimberger AB; McCortney K; Scholtens DM; Horbinski C
Blood; 2023 Mar; 141(11):1322-1336. PubMed ID: 36399711
[TBL] [Abstract][Full Text] [Related]
6. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.
Diaz M; Jo J
Curr Oncol Rep; 2022 Apr; 24(4):493-500. PubMed ID: 35179708
[TBL] [Abstract][Full Text] [Related]
7. The role of podoplanin in cancer-associated thrombosis.
Mir Seyed Nazari P; Riedl J; Pabinger I; Ay C
Thromb Res; 2018 Apr; 164 Suppl 1():S34-S39. PubMed ID: 29703483
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
Jo J; Diaz M; Horbinski C; Mackman N; Bagley S; Broekman M; Rak J; Perry J; Pabinger I; Key NS; Schiff D
Neuro Oncol; 2023 Aug; 25(8):1381-1394. PubMed ID: 37100086
[TBL] [Abstract][Full Text] [Related]
9. Venous thrombosis in patients with high-grade glioma.
Taillibert S; Taillandier L; Le Rhun E
Curr Opin Oncol; 2015 Nov; 27(6):516-21. PubMed ID: 26447877
[TBL] [Abstract][Full Text] [Related]
10. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation in the Setting of Primary and Metastatic Brain Tumors.
Mantia C; Zwicker JI
Cancer Treat Res; 2019; 179():179-189. PubMed ID: 31317488
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.
Huang Y; Ding H; Luo M; Li S; Xie C; Zhong Y; Li Z
Support Care Cancer; 2022 Jul; 30(7):6063-6069. PubMed ID: 35419733
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients.
Pan E; Tsai JS; Mitchell SB
Anticancer Res; 2009 Oct; 29(10):4309-13. PubMed ID: 19846992
[TBL] [Abstract][Full Text] [Related]
14. Thrombosis in brain tumors.
Jo JT; Schiff D; Perry JR
Semin Thromb Hemost; 2014 Apr; 40(3):325-31. PubMed ID: 24599439
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
Chai-Adisaksopha C; Linkins LA; ALKindi SY; Cheah M; Crowther MA; Iorio A
Thromb Haemost; 2017 Feb; 117(3):589-594. PubMed ID: 28078351
[TBL] [Abstract][Full Text] [Related]
16. IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Mandel JJ; Youssef M; Yust-Katz S; Patel AJ; Jalali A; Li Z; Wu J; Ludmir EB; de Groot JF
J Neurol Sci; 2021 Aug; 427():117538. PubMed ID: 34146775
[TBL] [Abstract][Full Text] [Related]
17. Venous Thromboembolism in Brain Tumor Patients.
Jeraq M; Cote DJ; Smith TR
Adv Exp Med Biol; 2017; 906():215-228. PubMed ID: 27628002
[TBL] [Abstract][Full Text] [Related]
18. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma.
Kaptein FHJ; Stals MAM; Kapteijn MY; Cannegieter SC; Dirven L; van Duinen SG; van Eijk R; Huisman MV; Klaase EE; Taphoorn MJB; Versteeg HH; Buijs JT; Koekkoek JAF; Klok FA
J Thromb Haemost; 2022 Jul; 20(7):1665-1673. PubMed ID: 35460331
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
Perry JR
Curr Opin Neurol; 2010 Dec; 23(6):592-6. PubMed ID: 20881488
[TBL] [Abstract][Full Text] [Related]
20. Contrasts in Glioblastoma-Venous Thromboembolism versus Bleeding Risk.
Muster V; Gary T
Cells; 2021 Jun; 10(6):. PubMed ID: 34200229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
